tazarotene topical / Generic mfg. 
Welcome,         Profile    Billing    Logout  

8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tazarotene topical / Generic mfg.
ChiCTR1900026812: Clinical Study of Post-Marketing Efficacy and Safety of Tazarotene Betamethasone Cream in the Treatment of Chronic Psoriasis Vulgaris

Completed
4
2299
 
Tazarotene and Betamethasone Dipropionate Cream (once daily)
Peking Union Medical College Hospital; Chongqing Huapont Pharm.Co., LTD, Chongqing Huapont Pharm.Co.,LTD
Chronic Psoriasis Vulgaris
 
 
ChiCTR1900027060: A Multicenter, Randomized, Open-Label Clinical Trial of Tazarotene and Betamethasone Dipropionate Cream Alone or Sequentially With Tazarotene Gel In the Treatment of Chronic Plaque Psoriasis

Completed
4
232
 
Tazarotene and Betamethasone Dipropionate Cream (once daily) ;Tazarotene and Betamethasone Dipropionate Cream (on weekends); Tazarotene Gel (on workdays)
Chinese Academy of Medical Sciences & Hospital for Skin Diseases; Chongqing Huapont Pharm.Co., Ltd., Chongqing Huapont Pharm.Co.,LTD
Chronic Plaque Psoriasis
 
 
NCT05555797: Excimer Laser With Topical Agents in Psoriasis Vulgaris

Not yet recruiting
4
30
NA
308nm Excimer laser, Tazarotene Topical Gel, Betamethasone Valerate
Assiut University
Psoriasis
09/23
09/23
ChiCTR1900024450: A phase III, multicenter, randomized, blind, controlled trial for efficacy and safety of tazarotene and betamethasone dipropionate cream in the treatment of subjects with psoriasis vulgaris

Completed
3
600
 
0.05% betamethasone dipropionate cream (Applied twice daily in the morning and evening) ;Placebo(once in the morning) +0.05% tazarotene gel (once in the evening) ;Placebo (once in the morning) + Tazarotene and Betamethasone Dipropionate Cream (once in the evening)
Chinese Academy of Medical Sciences & Hospital for Skin Diseases; Chongqing Huapont Pharm.Co., LTD, Chongqing Huapont Pharm.Co.,LTD
Psoriasis vulgaris
 
 
2013-003336-72: Clinical study for patients with cutaneous basal cell tumor evaluating the role of topical DAC-0600 plus Tazarotene Studio clinico per pazienti con tumore basocellulare della pelle per valutare il ruolo del trattamento locale con DAC-0060 in associazione a Tazarotene

Ongoing
2
80
Europe
ZORAC, DAC-0060, Gel, ZORAC
ISTITUTO EUROPEO DI ONCOLGIA, DAC srl
BASAL CELL CARCINOMA carcinoma basocellulare cutaneo, SKIN CANCER TUMORE CUTANEO, Diseases [C] - Cancer [C04]
 
 
NCT05314127: Efficacy of Tazarotene in Treatment of Verruca Plana

Recruiting
2
80
RoW
Tazarotene 0.1% Gel,Top, Imiquimod, Fluorouracil Cream, Petrolatum
Zagazig University
Warts Flat
10/22
12/22
GRI-0621-IPF-02, NCT06331624: Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

Recruiting
2
36
Europe, US
Tazarotene (GRI-0621), Placebo
GRI Bio Operations, Inc.
Idiopathic Pulmonary Fibrosis
01/25
01/25
NCT06015152: Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis

Completed
N/A
90
RoW
Tazarotene 0.045% Topical Application Lotion [ARAZLO]
Jinnah Postgraduate Medical Centre
Scalp Psoriasis
12/22
02/23

Download Options